|
|
 |
|
Viewing report
|
|
|
|
Head and Neck Cancer - Innovations to Change the Face of Treatment
Datamonitor, Feb 2005
The incidence of head and neck cancers is increasing. Surgery and radiation are employed with curative intent for early-stage lesions. Chemotherapy concurrent with radiation and surgery is the treatment of choice for unresectable disease. The market is characterised by a significant need for agents that reduce tumor size, curtail the extent of resection and delay or prevent tumor recurrence.
Collectively head and neck cancer patients represent a significant patient population. Improved survival by combining radiation and chemotherapy with Erbitux (Imclone/BMS/MercKGaA) has been reported. We believe that EGFR inhibition with Erbitux currently holds the most promise for head and neck cancer patients. AstraZeneca's Iressa (gefitinib) is in Phase III trials, but any survival benefit remains to be determined. Combinatorial approaches employing targeted treatments have the potential to improve patient outcomes though the optimal regimen has yet to be defined.
This report provides you with:
- Overview of the main tumor types for head and neck cancer, including epidemiology and staging
- Current treatment options by tumor site and stage, with assessment of clinical controversies
- Key recommendations in the areas of greatest unmet need, including the need for improvements in quality of life as well as increased survival
- Profiles of key head and neck therapies in late stage development, including forecasts of Erbitux, Iressa, and Advexin
Key report findings and highlights
- Platinum based therapy combined with radiation remains the standard of care for advanced stage patients. The survival advantage of this combination is not outstanding and is characterized by its toxicity. Therefore agents that provide even moderate improvements can expect significant uptake.
- Imclone/BMS/KGaA's Erbitux holds the most promise for head and neck cancer patients but cost may limit its uptake.
- Future developments for head and neck cancer will require integration of targeted therapy into current radiation and chemotherapy regimes. Key trials are examined.
Reasons to buy
- Identify market opportunities by exploring current unmet needs and key requirements for improving survival in head and neck cancer
- Understand the market impact of innovative therapies such as Imclone/BMS/Merck KGaA's Erbitux
- Plan product development based on an understanding of physician expectation of new therapies integration into current treatment regimes
'...The demonstration of the EGFR inhibitor Erbitux conferring survival benefit from radiation sensitization may inspire developers to initiate similar combinatorial trials, potentially improving therapeutic options and survival in these patients...'
'...Combinations of molecularly targeted molecules are being investigated, there is no firm clinical trial data as yet. However, I am quite confident that this approach will be the way forward in the treatment of head and neck cancer patients...'
Customers who bought this item also bought
European Head and Neck Cancer Therapeutics Markets
Cancer Head and Neck Cancer
Niche Cancers 2001: Head and Neck Cancer
Head and Neck Cancer Drug Pipeline Report
Cancer Therapeutics Markets
Head and Neck Cancer Therapy Area Pipeline Report
US Cancer Pain Report
Stakeholder Opinions: Esophageal Cancer Treatment Paradigms Need Revolution Not Evolution
The Cancer Clock
Cancer Therapies - Global Strategic Business Report
Cancer Chemotherapy: Basic Science to the Clinic
Gastric Cancer - Targeted Therapies Compete for First-to-Market Status
|
|
|
|
